Equities analysts predict that Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Rating) will announce $6.24 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Sensus Healthcare’s earnings, with the lowest sales estimate coming in at $5.22 million and the highest estimate coming in at $7.25 million. Sensus Healthcare reported sales of $3.07 million in the same quarter last year, which indicates a positive year over year growth rate of 103.3%. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Sensus Healthcare will report full year sales of $32.12 million for the current financial year, with estimates ranging from $31.57 million to $32.66 million. For the next year, analysts forecast that the firm will report sales of $36.61 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Sensus Healthcare.
Sensus Healthcare (NASDAQ:SRTS – Get Rating) last posted its quarterly earnings results on Thursday, February 10th. The company reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.14 by $0.18. Sensus Healthcare had a return on equity of 18.88% and a net margin of 15.23%. The company had revenue of $13.03 million for the quarter, compared to analysts’ expectations of $11.01 million. During the same period last year, the firm earned $0.06 earnings per share.
In other news, COO Nicolas Soro sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 9th. The stock was sold at an average price of $10.20, for a total value of $102,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Joseph C. Sardano sold 50,274 shares of the firm’s stock in a transaction that occurred on Wednesday, March 9th. The shares were sold at an average price of $10.19, for a total value of $512,292.06. The disclosure for this sale can be found here. Insiders have sold a total of 114,056 shares of company stock valued at $1,151,818 over the last ninety days. 24.30% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in Sensus Healthcare by 31.2% in the 4th quarter. Geode Capital Management LLC now owns 90,964 shares of the company’s stock valued at $656,000 after purchasing an additional 21,632 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Sensus Healthcare by 47.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 68,298 shares of the company’s stock valued at $493,000 after purchasing an additional 22,015 shares during the period. State Street Corp grew its position in shares of Sensus Healthcare by 299.4% in the fourth quarter. State Street Corp now owns 42,287 shares of the company’s stock valued at $305,000 after purchasing an additional 31,700 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Sensus Healthcare in the fourth quarter valued at $281,000. Finally, Morgan Stanley boosted its holdings in Sensus Healthcare by 340.4% in the first quarter. Morgan Stanley now owns 44,894 shares of the company’s stock valued at $172,000 after acquiring an additional 34,699 shares during the last quarter. 14.64% of the stock is owned by institutional investors and hedge funds.
Sensus Healthcare stock traded down $0.27 during midday trading on Friday, reaching $9.15. The company’s stock had a trading volume of 212,215 shares, compared to its average volume of 449,793. The stock’s 50-day moving average is $9.87. Sensus Healthcare has a fifty-two week low of $3.08 and a fifty-two week high of $11.96. The stock has a market cap of $152.44 million, a P/E ratio of 38.13 and a beta of 0.30.
Sensus Healthcare Company Profile (Get Rating)
Sensus Healthcare, Inc manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
- Get a free copy of the StockNews.com research report on Sensus Healthcare (SRTS)
- 3 Recession-Proof Stocks to Buy Now
- MarketBeat: Week in Review 4/4 – 4/8
- 3 Best Life Sciences Stocks to Buy Now
- The Institutional Insiders Are Buying WD-40 Company
- What’s Behind The Latest Surge In GameStop (NYSE: GME)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.